QT interval prolongation by non-cardiovascular drugs: Issues and solutions for novel drug development

Pharmaceutical Science and Technology Today

Volumn 2, Issue 7, 1999, Pages 270-280

  Crumb, William ^a   Cavero, Icilio ^b  

^a ZENAS TECHNOLOGIES LLC   (United States)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR AGENT;

CORONARY RISK; DOG; ELECTROCARDIOGRAM; HEART DEATH; HEART ELECTROPHYSIOLOGY; HUMAN; LONG QT SYNDROME; NONHUMAN; QT INTERVAL; REVIEW;

EID: 0033166783     PISSN: 14615347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1461-5347(99)00172-8     Document Type: Review

References (40)

1. Committee for Proprietary Medicinal Products (1997) CPMP/986/96
2. Lindquist, M. and Edwards, R.J. (1997) Lancet 49, 13-22
3. Faber, T.S. et al. (1994) Drug Safety 11, 463-476
4. Vincent, G.M. (1998) Annu. Rev. Med. 49, 263-274
5. Katz, A.M. (1993) New Engl. J. Med. 17, 1244-1251
6. Yeola, S.W. and Snyders, D.J. (1997) Cardiovasc. Res. 33, 540-547
7. Fiset, C. et al. (1997) J. Physiol. 50, 51-64
8. Dixon, J.E. et al. (1996) Circ. Res. 79, 659-668
9. Wang, Z. et al. (1999) Circ. Res. 84, 551-561
10. Kazufumi, T. and Curtis, M.J.J. (1991) Cardiovasc. Pharmacol. 18, 445-456
11. Freeman, L.C. et al. (1997) J. Cardiovasc. Electrophysiol. 8, 872-883
12. Dixon, J.E. and McKinnon, D. (1994) Circ. Res. 75, 252-260
13. Crumb, W.J., Jr et al. (1995) Circ. Res. 77, 950-956
14. Feng, J. et al. (1997) Circ. Res. 80, 572-579
15. Ficker, E. et al. (1998) Circ. Res. 82, 386-395
16. Wang, Q. et al. (1997) Curr. Opin. Cardiol. 12, 310-320
17. Iost, N. et al. (1998) Cardiovasc. Res 40, 508-515
18. Keating, J.M.T. (1996) Medicine 75, 1-5
19. Zipes, D.P. and Wellens, H.J.J. (1998) Circulation 98, 2334-2351
20. Dawoddu, A.A. et al. (1996) Int. J. Cardiol. 54, 237-249
21. Vitola, J. et al. (1998) J. Cardiovasc. Electrophysiol. 9, 1109-1113
22. Hunt, N. and Stern, T.A. (1995) Psychosomatics 36, 541-549
23. Bailey, D.S. et al. (1998) Curr. Opin. Biotechnol. 9, 595-601
24. Cavero, I. et al. Drug Safety (in press)
25. Priori, S.G. (1998) J. Cardiovasc. Electrophysiol. 9, 1114-1116
26. De Bruyne, M.C. et al. (1999) Eur. Heart J. 20, 278-284
27. Elming, H. et al. (1998) Eur. Heart J. 19, 1391-1400
28. Dollery, C.T. (1999) Br. J. Clin. Pharmacol. 47, 5-6
29. Natsukawa, T. et al. (1998) Gen. Pharmacol. 30, 137-142
30. Nishio, M. et al. (1998) J. Pharmacol. Exp. Ther. 287, 293-300
31. Botstein, P. (1993) Am. J. Cardiol. 72, 50B-52B
32. Salata, J.J. et al. (1995) Circ. Res. 76, 110-119
33. Ducic, I. et al. (1997) J. Cardiovasc. Pharmacol. 30, 42-54
34. Crumb, W.J., Jr (1998) Clin. Invest. Med. S3
35. Roden, D.M. (1993) Clin. Cardiol. 16, 683-686
36. Tande, P.M. et al. (1990) J. Cardiovasc. Pharmacol. 16, 401-410
37. Ohler, A. et al. (1994) Naunyn-Schmiedeberg's Arch. Pharmacol. 349, 602-610
38. Pressler, M.L. et al. (1995) J. Cardiovasc. Electrophysiol. 6, 443-454
39. Kiehn, J. et al. (1996) Circulation 94, 2572-2579
40. Capucci, A. et al. (1998) J. Cardiovasc. Electrophysiol. 9, S109-S120